Product
MDR-102
1 clinical trial
1 indication
Indication
Kidney Transplant RejectionClinical trial
A Phase 2/3, Prospective, Randomized, Multi-center, Open-Label, Controlled Trial to Assess the Efficacy & Safety of Cellular Immunotherapy With MDR-102 for Induction of Immune Quiescence™in Recipients of HLA-mismatched, LD Kidney TransplantsStatus: Not yet recruiting, Estimated PCD: 2026-09-01